A potential prognostic marker for hematologic neoplasms: CD58
CD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells. Aberrant expression of CD58 has been demonstrated to exert a significant impact on the prognosis of hematological tumors, in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1586842/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | CD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells. Aberrant expression of CD58 has been demonstrated to exert a significant impact on the prognosis of hematological tumors, including leukemia and lymphoma. Furthermore, this aberrant expression has been associated with drug resistance and immune rejection in CAR cell therapy. In this article, we will explore the future of CD58 in hematological oncology by describing its function in immune cells, its impact on hematological oncology and immunotherapies such as CAR cell therapy. |
|---|---|
| ISSN: | 2234-943X |